Department Of Urology 5

201. Urological impact of flozins (SGLT2 inhibitors): an EAU Endourology review of risks, side effects and clinical considerations
202. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
203. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
204. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
205. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
206. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
207. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
208. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
209. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
210. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
211. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
212. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
213. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
214. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
215. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
216. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
217. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
218. How does RIRS impact on stent-related symptoms? Insights from a prospective observational study by EAU-YAU endourology and urolithiasis working group
219. Relocation of big stone fragments with direct-in scope suction
220. Relocation of big stone fragments with direct-in scope suction
221. Relocation of big stone fragments with direct-in scope suction
222. Relocation of big stone fragments with direct-in scope suction
223. Relocation of big stone fragments with direct-in scope suction
224. Relocation of big stone fragments with direct-in scope suction
225. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
226. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
227. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
228. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
229. The Model of Acute Obstructive Pyelonephritis for Studying Bacterial Translocation of E. coli from Gastroenteric Tract
230. Patient perspectives on vasectomy: findings from a TikTok® content analysis
231. Patient perspectives on vasectomy: findings from a TikTok® content analysis
232. Patient perspectives on vasectomy: findings from a TikTok® content analysis
233. Patient perspectives on vasectomy: findings from a TikTok® content analysis
234. Patient perspectives on vasectomy: findings from a TikTok® content analysis
235. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
236. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
237. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
238. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
239. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
240. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
241. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
242. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
243. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
244. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
245. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
246. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
247. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
248. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
249. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
250. Ureteroscopy for stone disease in the elderly (≥ 80 years): Outcomes of a multicentre study from YAU and EAU endourology groups
1 3 4 5 6 7 8